| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiration, Artificial | 26 | 2021 | 22116 | 1.20 | Why? |
| Extracorporeal Membrane Oxygenation | 17 | 2020 | 5002 | 1.08 | Why? |
| Respiratory Mechanics | 4 | 2020 | 585 | 1.07 | Why? |
| Respiratory Insufficiency | 13 | 2020 | 7301 | 1.04 | Why? |
| Ventilator-Induced Lung Injury | 5 | 2017 | 260 | 0.95 | Why? |
| Neuromuscular Blockade | 1 | 2019 | 66 | 0.76 | Why? |
| Carbon Dioxide | 3 | 2018 | 917 | 0.63 | Why? |
| Long Term Adverse Effects | 1 | 2017 | 119 | 0.63 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.59 | Why? |
| Lung Injury | 4 | 2019 | 919 | 0.58 | Why? |
| Nomograms | 1 | 2021 | 790 | 0.55 | Why? |
| Precision Medicine | 3 | 2019 | 1477 | 0.51 | Why? |
| Bayes Theorem | 3 | 2019 | 3237 | 0.51 | Why? |
| Alveolar Epithelial Cells | 2 | 2020 | 1445 | 0.48 | Why? |
| Cognition Disorders | 1 | 2017 | 574 | 0.46 | Why? |
| Cannula | 1 | 2017 | 750 | 0.45 | Why? |
| Noninvasive Ventilation | 3 | 2021 | 2329 | 0.42 | Why? |
| Analgesics, Opioid | 1 | 2019 | 1070 | 0.38 | Why? |
| Tidal Volume | 5 | 2020 | 565 | 0.38 | Why? |
| Opioid-Related Disorders | 1 | 2019 | 1185 | 0.33 | Why? |
| Positive-Pressure Respiration | 6 | 2018 | 1160 | 0.32 | Why? |
| Diaphragm | 2 | 2018 | 232 | 0.29 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 2426 | 0.29 | Why? |
| Peptidyl-Dipeptidase A | 5 | 2020 | 9659 | 0.28 | Why? |
| Receptors, Virus | 2 | 2020 | 5659 | 0.26 | Why? |
| Heparin | 3 | 2021 | 2600 | 0.26 | Why? |
| Oxygen | 2 | 2017 | 3715 | 0.26 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.24 | Why? |
| Recombinant Proteins | 3 | 2020 | 3786 | 0.22 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.21 | Why? |
| Antibodies, Anticardiolipin | 1 | 2021 | 208 | 0.20 | Why? |
| Humans | 71 | 2021 | 930598 | 0.20 | Why? |
| Critical Care | 3 | 2020 | 14081 | 0.20 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.20 | Why? |
| Neuropeptide Y | 1 | 2018 | 14 | 0.19 | Why? |
| Intensive Care Units | 7 | 2020 | 29594 | 0.19 | Why? |
| alpha-Defensins | 1 | 2018 | 35 | 0.18 | Why? |
| Orthomyxoviridae Infections | 2 | 2018 | 1001 | 0.18 | Why? |
| Thrombosis | 4 | 2021 | 7504 | 0.18 | Why? |
| Severe Acute Respiratory Syndrome | 3 | 2020 | 12361 | 0.18 | Why? |
| Medical Records | 1 | 2021 | 513 | 0.18 | Why? |
| Phagocytes | 1 | 2018 | 180 | 0.17 | Why? |
| Dyspnea | 4 | 2019 | 3847 | 0.17 | Why? |
| Hyperventilation | 1 | 2017 | 59 | 0.17 | Why? |
| Pulmonary Gas Exchange | 2 | 2017 | 414 | 0.17 | Why? |
| High-Frequency Ventilation | 1 | 2017 | 57 | 0.17 | Why? |
| Interactive Ventilatory Support | 1 | 2016 | 25 | 0.17 | Why? |
| Randomized Controlled Trials as Topic | 7 | 2020 | 10649 | 0.16 | Why? |
| Zebrafish | 1 | 2017 | 181 | 0.16 | Why? |
| Standard of Care | 2 | 2020 | 1297 | 0.16 | Why? |
| Bed Occupancy | 1 | 2020 | 476 | 0.16 | Why? |
| Antibodies, Antiphospholipid | 1 | 2021 | 519 | 0.16 | Why? |
| Carboxypeptidases | 2 | 2005 | 148 | 0.15 | Why? |
| Acute Lung Injury | 2 | 2017 | 904 | 0.15 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 520 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.14 | Why? |
| Climate | 1 | 2020 | 557 | 0.14 | Why? |
| Dexamethasone | 3 | 2020 | 2055 | 0.14 | Why? |
| Antiphospholipid Syndrome | 1 | 2021 | 533 | 0.14 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.14 | Why? |
| Coronavirus Infections | 14 | 2020 | 253789 | 0.14 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2019 | 422 | 0.14 | Why? |
| Transfusion Reaction | 1 | 2017 | 245 | 0.14 | Why? |
| Myocardial Ischemia | 1 | 2021 | 781 | 0.14 | Why? |
| Glucocorticoids | 2 | 2020 | 4431 | 0.14 | Why? |
| Anticoagulants | 5 | 2021 | 9563 | 0.13 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.13 | Why? |
| Heart Failure | 3 | 2021 | 6638 | 0.13 | Why? |
| Rats | 2 | 2019 | 2764 | 0.13 | Why? |
| Developed Countries | 1 | 2017 | 500 | 0.13 | Why? |
| Exhalation | 1 | 2016 | 441 | 0.13 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.12 | Why? |
| Receptors, CXCR3 | 1 | 2012 | 159 | 0.12 | Why? |
| Sepsis | 4 | 2018 | 3517 | 0.12 | Why? |
| Sex Characteristics | 1 | 2020 | 1120 | 0.12 | Why? |
| Viral Envelope Proteins | 2 | 2020 | 3539 | 0.12 | Why? |
| Attitude of Health Personnel | 2 | 2019 | 4741 | 0.11 | Why? |
| Shock, Cardiogenic | 1 | 2018 | 700 | 0.11 | Why? |
| Radiography | 2 | 2018 | 1576 | 0.11 | Why? |
| Science | 1 | 2018 | 463 | 0.11 | Why? |
| Hospital Mortality | 6 | 2021 | 22087 | 0.11 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2017 | 698 | 0.10 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2020 | 37182 | 0.10 | Why? |
| Influenza A virus | 2 | 2021 | 2234 | 0.10 | Why? |
| Interleukin-10 | 1 | 2017 | 1409 | 0.10 | Why? |
| Oxygen Consumption | 1 | 2014 | 711 | 0.10 | Why? |
| Hypoxia | 3 | 2018 | 3626 | 0.09 | Why? |
| Chemokine CXCL10 | 1 | 2012 | 565 | 0.09 | Why? |
| Adult | 19 | 2021 | 244371 | 0.09 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
| High-Throughput Screening Assays | 1 | 2017 | 1783 | 0.09 | Why? |
| Ventilators, Mechanical | 1 | 2020 | 2193 | 0.09 | Why? |
| Income | 1 | 2017 | 1564 | 0.09 | Why? |
| Critical Illness | 9 | 2021 | 17281 | 0.09 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.09 | Why? |
| Disease Models, Animal | 5 | 2018 | 10998 | 0.08 | Why? |
| Hypercapnia | 2 | 2018 | 172 | 0.08 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.08 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.08 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.08 | Why? |
| Animals | 11 | 2020 | 78931 | 0.07 | Why? |
| Statistics, Nonparametric | 2 | 2020 | 1008 | 0.07 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.07 | Why? |
| Lung | 7 | 2020 | 31049 | 0.07 | Why? |
| Analysis of Variance | 3 | 2020 | 950 | 0.07 | Why? |
| Fluid Therapy | 2 | 2020 | 628 | 0.07 | Why? |
| Research | 1 | 2017 | 2115 | 0.07 | Why? |
| Hemorrhage | 3 | 2021 | 3013 | 0.07 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.06 | Why? |
| Oxygen Inhalation Therapy | 1 | 2017 | 3629 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| China | 2 | 2021 | 50654 | 0.06 | Why? |
| Mice | 7 | 2020 | 21357 | 0.06 | Why? |
| Prospective Studies | 8 | 2020 | 43301 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Barotrauma | 1 | 2004 | 97 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Pandemics | 18 | 2020 | 389249 | 0.06 | Why? |
| Male | 20 | 2021 | 367725 | 0.06 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.06 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.06 | Why? |
| Treatment Outcome | 8 | 2020 | 51732 | 0.06 | Why? |
| Female | 18 | 2021 | 380317 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Gene Deletion | 2 | 2018 | 430 | 0.06 | Why? |
| Lung Diseases | 2 | 2005 | 2361 | 0.06 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.06 | Why? |
| Sex Chromosomes | 1 | 2020 | 8 | 0.05 | Why? |
| Continuous Positive Airway Pressure | 1 | 2010 | 1187 | 0.05 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.05 | Why? |
| Multiple Organ Failure | 2 | 2018 | 1724 | 0.05 | Why? |
| Aged | 12 | 2021 | 215776 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.05 | Why? |
| Neutrophils | 2 | 2017 | 5476 | 0.05 | Why? |
| Hydrocortisone | 2 | 2020 | 1790 | 0.05 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.05 | Why? |
| Receptors, Neuropeptide Y | 1 | 2018 | 4 | 0.05 | Why? |
| Survival Analysis | 3 | 2021 | 7592 | 0.05 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.05 | Why? |
| Artificial Organs | 1 | 2018 | 18 | 0.05 | Why? |
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2018 | 26 | 0.05 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 350 | 0.05 | Why? |
| Angiotensin II | 2 | 2020 | 601 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.04 | Why? |
| Cells, Cultured | 2 | 2020 | 5835 | 0.04 | Why? |
| Blood Vessels | 1 | 2020 | 228 | 0.04 | Why? |
| Chest Wall Oscillation | 1 | 2017 | 17 | 0.04 | Why? |
| Life Support Care | 1 | 2019 | 161 | 0.04 | Why? |
| Sample Size | 1 | 2020 | 518 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Embryo, Nonmammalian | 1 | 2017 | 36 | 0.04 | Why? |
| Vagotomy | 1 | 2016 | 4 | 0.04 | Why? |
| Atrophy | 1 | 2018 | 192 | 0.04 | Why? |
| Gonadal Steroid Hormones | 1 | 2020 | 328 | 0.04 | Why? |
| Drug Synergism | 1 | 2020 | 833 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Prone Position | 2 | 2020 | 1861 | 0.04 | Why? |
| Mice, Knockout | 2 | 2017 | 1815 | 0.04 | Why? |
| Hematologic Neoplasms | 1 | 2010 | 2105 | 0.04 | Why? |
| Hemofiltration | 1 | 2018 | 155 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 98 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Benchmarking | 1 | 2020 | 627 | 0.04 | Why? |
| Membrane Glycoproteins | 1 | 2005 | 2273 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.04 | Why? |
| Intubation | 1 | 2017 | 437 | 0.04 | Why? |
| Influenza B virus | 1 | 2021 | 815 | 0.04 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.04 | Why? |
| United States | 2 | 2019 | 46150 | 0.04 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Ultrasonography, Doppler | 1 | 2018 | 406 | 0.03 | Why? |
| Geography, Medical | 1 | 2017 | 537 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Vero Cells | 2 | 2020 | 14117 | 0.03 | Why? |
| Catheterization, Central Venous | 1 | 2018 | 458 | 0.03 | Why? |
| Organoids | 1 | 2020 | 840 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Mycobacterium avium Complex | 1 | 1993 | 61 | 0.03 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.03 | Why? |
| Rabbits | 1 | 2016 | 1171 | 0.03 | Why? |
| Blood Gas Analysis | 1 | 2016 | 893 | 0.03 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 1993 | 59 | 0.03 | Why? |
| Mice, Inbred Strains | 1 | 2012 | 136 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2018 | 1326 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Patient Acuity | 1 | 2018 | 1755 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
| Airway Management | 1 | 2020 | 1298 | 0.03 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1993 | 260 | 0.03 | Why? |
| Protein Array Analysis | 1 | 2012 | 387 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Hemodynamics | 1 | 2018 | 1562 | 0.03 | Why? |
| Taiwan | 1 | 2018 | 2556 | 0.02 | Why? |
| Health Care Surveys | 1 | 2019 | 2942 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Rats, Sprague-Dawley | 1 | 2012 | 987 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.02 | Why? |
| Equipment Design | 1 | 2020 | 3095 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2020 | 1956 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2018 | 1530 | 0.02 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2012 | 492 | 0.02 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.02 | Why? |
| Arrhythmias, Cardiac | 1 | 2021 | 2510 | 0.02 | Why? |
| Heart Transplantation | 1 | 2018 | 1293 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| Internationality | 1 | 2019 | 3297 | 0.02 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Acids | 1 | 2005 | 22 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.02 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.02 | Why? |
| Transgenes | 1 | 2005 | 227 | 0.02 | Why? |
| Receptor, Angiotensin, Type 1 | 1 | 2005 | 160 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Chronology as Topic | 1 | 2003 | 13 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Capillary Permeability | 1 | 2005 | 277 | 0.02 | Why? |
| Receptor, Angiotensin, Type 2 | 1 | 2005 | 190 | 0.02 | Why? |
| Bacteremia | 1 | 1993 | 1372 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Pedigree | 1 | 2003 | 502 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| SARS Virus | 1 | 2005 | 13021 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Pulmonary Edema | 1 | 2005 | 430 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Disease Progression | 2 | 2012 | 13580 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Genetic Variation | 1 | 1993 | 3919 | 0.01 | Why? |
| Risk Factors | 2 | 2018 | 71621 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Mice, Transgenic | 1 | 2005 | 2739 | 0.01 | Why? |
| Immunohistochemistry | 1 | 2005 | 2275 | 0.01 | Why? |
| Family Health | 1 | 2003 | 731 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Blotting, Southern | 1 | 1993 | 18 | 0.01 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 1993 | 78 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Prognosis | 1 | 2014 | 32490 | 0.01 | Why? |
| Pneumonia | 1 | 2010 | 5652 | 0.01 | Why? |
| Canada | 1 | 2003 | 6018 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Cough | 1 | 2003 | 4891 | 0.01 | Why? |
| Fever | 1 | 2003 | 7795 | 0.00 | Why? |
| Contact Tracing | 1 | 2003 | 8448 | 0.00 | Why? |
| Aged, 80 and over | 1 | 2012 | 88759 | 0.00 | Why? |